(OLMA) Olema Pharmaceuticals - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.195m USD | Total Return: 148.9% in 12m
Avg Turnover: 14.8M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Share dilution 21.2% YoY
Altman Z'' -14.70 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
No distinct edge detected
Olema Pharmaceuticals (OLMA) is a clinical-stage biopharmaceutical firm headquartered in San Francisco, specializing in targeted therapies for women’s cancers. The company’s primary focus is the development of palazestrant, a selective estrogen receptor degrader (SERD) currently undergoing Phase 3 clinical trials for the treatment of ER+/HER2- metastatic breast cancer. Additionally, Olema is investigating combination treatments involving CDK4/6 and PI3Ka inhibitors, alongside a Phase 1 program for OP-3136, a KAT6 inhibitor targeting various solid tumors.
The biotechnology sector often utilizes a high-risk, high-reward business model where significant capital is directed toward R&D and clinical trials prior to achieving commercial revenue. Success in this industry typically depends on navigating the multi-phase FDA approval process and securing intellectual property protections for novel molecular entities. For a more comprehensive look at these financial risk factors, you may want to explore the data available on ValueRay.
- Palazestrant Phase 3 OPERA-01 clinical trial results determine long-term commercial viability
- FDA approval timeline for palazestrant governs transition to revenue-generating stage
- Combination therapy trial data influences market share potential in metastatic breast cancer
- R&D expenditure and cash runway dictate future equity financing requirements
- KAT6 inhibitor pipeline progress diversifies risk beyond lead endocrine therapy candidate
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.28 > 0.02 and ΔFCF/TA 2.45 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.28 > 3% & CFO -148.7m > Net Income -185.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.88 > 1.5 & < 3 |
| Outstanding Shares: last quarter (102.8m) vs 12m ago 20.34% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.09%; Δ -0.09% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.88 (Total Current Assets 513.2m - Total Current Liabilities 47.2m) / Total Assets 530.6m |
| B: -1.23 (Retained Earnings -650.6m / Total Assets 530.6m) |
| C: -0.42 (EBIT TTM -198.2m / Avg Total Assets 470.1m) |
| D: -12.98 (Book Value of Equity -651.1m / Total Liabilities 50.2m) |
| Altman-Z'' = -14.70 = D |
As of May 30, 2026, the stock is trading at USD 13.19 with a total of 1,496,406 shares traded.
Over the past week, the price has changed by -6.19%,
over one month by -6.72%,
over three months by -45.50% and
over the past year by +148.87%.
Olema Pharmaceuticals has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy OLMA.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 41.8 | 217.1% |
P/B = 2.4887
Revenue TTM = 0.0 USD
EBIT TTM = -198.2m USD
EBITDA TTM = -197.7m USD
Long Term Debt = 3.00m USD (from longTermDebt, last quarter)
Short Term Debt = 956k USD (from shortTermDebt, last quarter)
Debt = 4.91m USD (corrected: LT Debt 3.00m + ST Debt 956k) + Leases 956k
Net Debt = -500.4m USD (calculated: Debt 4.91m - CCE 505.3m)
Enterprise Value = 694.5m USD (1.19b + Debt 4.91m - CCE 505.3m)
Interest Coverage Ratio = unknown (Ebit TTM -198.2m / Interest Expense TTM 0.0)
EV/FCF = -4.67x (Enterprise Value 694.5m / FCF TTM -148.7m)
FCF Yield = -21.42% (FCF TTM -148.7m / Enterprise Value 694.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 1.31 (Enterprise Value 694.5m / Total Assets 530.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 4.91m)
Taxrate = 21.0% (US default 21%)
NOPAT = -156.5m (EBIT -198.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.88 (Total Current Assets 513.2m / Total Current Liabilities 47.2m)
Debt / Equity = 0.01 (Debt 4.91m / totalStockholderEquity, last quarter 480.5m)
Debt / EBITDA = 2.53 (negative EBITDA) (Net Debt -500.4m / EBITDA -197.7m)
Debt / FCF = 3.36 (negative FCF - burning cash) (Net Debt -500.4m / FCF TTM -148.7m)
Total Stockholder Equity = 402.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.38% (Net Income -185.2m / Total Assets 530.6m)
RoE = -17.57% (Net Income TTM -185.2m / Total Stockholder Equity 1.05b)
RoCE = -18.75% (EBIT -198.2m / Capital Employed (Equity 1.05b + L.T.Debt 3.00m))
RoIC = -44.47% (negative operating profit) (NOPAT -156.5m / Invested Capital 352.0m)
WACC = 6.24% (E(1.19b)/V(1.20b) * Re(6.27%) + D(4.91m)/V(1.20b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 6.27% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.75 | Cagr: 44.49%
[DCF] Fair Price = unknown (Cash Flow -148.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.02 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.56 | Chg30d=N/A | Revisions=+11% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-0.57 | Chg30d=N/A | Revisions=+11% | Analysts=10
EPS current Year (2026-12-31): EPS=-2.24 | Chg30d=N/A | Revisions=+0% | GrowthEPS=-19.8% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.33 | Chg30d=N/A | Revisions=+0% | GrowthEPS=-3.8% | GrowthRev=+1388.0%
[Analyst] Revisions Ratio: +11%